Shanghai, China · Founded 2020 · In IPO Registration
Developer and manufacturer of CAR-T cell therapies and innovative treatment platforms designed for solid tumors and hematological cancers. Immunofoco Biotechnology is based in Shanghai, China and was founded in 2020. Its last reported valuation was $298 million in Feb 2026. It has raised $139 million.
Last reported valuation
$298.1M
Oct 2026
Priced at
—
Total raised
$138.8M
Last round
—
Team — not yet on record
No current team members for Immunofoco Biotechnology are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Immunofoco Biotechnology with a free account
·The complete investor list: 27 names
·Watch Immunofoco Biotechnology: the Monday email on marks, rounds and moves
